Xylong Kids, spray 0.05 mg+5 mg/dose 15 ml

Pharmacotherapeutic group: anticongestant

ATC code: R01AB

Pharmacodynamics:

Xylometazoline belongs to the group of local vasoconstrictors (decongestants) with alpha-adrenomimetic activity causes narrowing of the blood vessels of the nasal cavity mucosa restores the patency of nasal passages facilitates nasal breathing. The action of the drug usually comes within a few minutes after application and lasts up to 10 hours.

Dexpanthenol is a B vitamin and a derivative of pantothenic acid. Dexpanthenol converts in the body to pantothenic acid which is part of coenzyme A and is involved in the processes of acetylation, carbohydrate and fat metabolism in the synthesis of acetylcholine, corticosteroids, porphyrins; it stimulates skin mucous membrane regeneration, normalizes cellular metabolism, accelerates mitosis and increases the strength of collagen fibers. It has a regenerating metabolic and mild anti-inflammatory effect.

Pharmacokinetics:

Xylomethasoline is practically not absorbed when applied topically, plasma concentrations are so low that they cannot be determined by modern analytical methods.

Dexpanthenol when applied topically is rapidly absorbed by the skin and converted to pantothenic acid binds to plasma proteins (mainly beta globulin and albumin). Its concentration in blood is 05-1 mg/L in serum is 100 µg/L. Pantothenic acid is not metabolized in the body (except for inclusion in Co-A) is excreted unchanged.

Indications

Used for acute respiratory diseases with symptoms of rhinitis, acute allergic rhinitis, vasomotor rhinitis, sinusitis with otitis media (as part of combination therapy to reduce swelling of the nasopharyngeal mucosa) to facilitate rhinoscopy to restore impaired nasal breathing; after surgical interventions in the nasal cavity.

Pharmacological effect

Pharmacotherapeutic group: Anticongestant

ATX code: R01AB

Pharmacodynamics:

Xylometazoline belongs to the group of local vasoconstrictors (decongestants) with alpha-adrenomimetic activity, causes constriction of the blood vessels of the nasal mucosa, restores the patency of the nasal passages, facilitates nasal breathing. The effect of the drug usually occurs within a few minutes after its use and lasts up to 10 hours.

Dexpanthenol is a B vitamin and is a derivative of pantothenic acid. Dexpanthenol is converted in the body into pantothenic acid, which is an integral part of coenzyme A and participates in the processes of acetylation of carbohydrate and fat metabolism in the synthesis of acetylcholine, corticosteroids and porphyrins; stimulates the regeneration of skin and mucous membranes, normalizes cellular metabolism, accelerates mitosis and increases the strength of collagen fibers. It has a regenerating metabolic and mild anti-inflammatory effect.

Pharmacokinetics:

When applied topically, xylometazoline is practically not absorbed; plasma concentrations are so small that they cannot be determined by modern analytical methods.

When applied topically, dexpanthenol is quickly absorbed by the skin and converted into pantothenic acid and binds to plasma proteins (mainly beta-globulin and albumin). Its concentration in the blood is 05-1 mg/l, in the blood serum – 100 μg/l. Pantothenic acid is not metabolized in the body (except for inclusion in Co-A) and is excreted unchanged.

Special instructions

Before use, it is necessary to clean the nasal passages.

The duration of use of the drug in children is determined after consultation with a doctor.

Impact on the ability to drive vehicles. Wed and fur.:

When using the drug in accordance with these instructions for use, the drug does not affect the ability to drive vehicles; however, if adverse events occur, you should refrain from performing these types of activities.

Active ingredient

Xylometazoline, [Dexpanthenol]

Composition

Per dose:

Active ingredients: xylometazoline hydrochloride – 0.050 mg, dexpanthenol – 5,000 mg.

Excipients: sodium citrate dihydrate – 0.509 mg, sodium chloride – 0.250 mg, hypromellose – 0.100 mg, benzalkonium chloride – 0.015 mg, citric acid monohydrate – 0.350 mg, purified water up to 100 µl.

Pregnancy

The drug should not be used during pregnancy.

Avoid using the drug during breastfeeding.

Contraindications

Hypersensitivity to the components of the drug arterial hypertension tachycardia severe atherosclerosis hyperthyroidism glaucoma atrophic rhinitis dry rhinitis porphyria prostatic hyperplasia surgical interventions on the meninges (history) simultaneous use with monoamine oxidase inhibitors (MAO) and tricyclic antidepressants children under 2 years of age.

With caution:

Diabetes mellitus pheochromocytoma diseases of the cardiovascular system (including coronary heart disease) increased sensitivity to the action of adrenergic drugs accompanied by insomnia, dizziness, arrhythmia, tremor, increased blood pressure.

Side Effects

The adverse events presented below are listed depending on the anatomical and physiological classification and frequency of occurrence.

The frequency of occurrence is defined as follows: very common (≥ 1/10) common (≥ 1/100 to < 1/10) uncommon (≥ 1/1000 to < 1/100) rare (≥ 1/10,000 to < 1/1000) very rare (< 1/10,000) unknown (frequency not known based on available data).

Nervous system disorders:

Very rare: anxiety insomnia headache fatigue (drowsiness) hallucinations (mainly in children).

Cardiovascular system disorders:

Rarely: palpitations, tachycardia, increased blood pressure.

Very rare: arrhythmia

Respiratory system disorders:

Very rare: swelling of the nasal mucosa, hypersecretion, nosebleeds.

Frequency unknown: burning and dryness of the nasal mucosa, sneezing.

Disorders of the musculoskeletal system:

Very rare: convulsions (especially in children).

Immune system disorders:

Very rare: allergic reactions (angioedema, skin rash, itching).

If any of the side effects indicated in the instructions get worse or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

Concomitant use of MAO inhibitors and tricyclic antidepressants may lead to an increase in blood pressure due to the effects of these drugs on the cardiovascular system.

Overdose

In cases of overdose or accidental oral use, the following symptoms may occur: mydriasis nausea vomiting cyanosis fever convulsions tachycardia cardiac arrhythmias vascular insufficiency cardiac arrest hypertension pulmonary edema respiratory dysfunction hallucinations.

Patients may also experience symptoms of central nervous system depression accompanied by drowsiness, decreased body temperature, bradycardia, shock, respiratory arrest, and coma.

Treatment

The use of activated carbon, gastric lavage, oxygen ventilation of the lungs. To lower blood pressure, 5 mg of phentolamine in 09% sodium chloride solution is prescribed by slow intravenous administration or 100 mg of phentolamine orally. Vasoconstrictor drugs are contraindicated. If necessary, antipyretic and anticonvulsants are used.

Storage conditions

At a temperature not exceeding 25 °C.

Keep out of the reach of children.

Shelf life

25 months.

Do not use after the expiration date indicated on the package.

Manufacturer

Pharmstandard-Leksredstva, Russia